Skip to Content

U.S. Government Moves Forward with Tests of Novel Zika Vaccine

Flexible vaccines made from DNA could be used to counter emerging threats.
April 3, 2017
A healthy patient receives an investigational DNA vaccine developed by government researchers via a needle-free injection.

The U.S. government says it will move forward with wider tests of its Zika vaccine after the results from a safety study initiated last summer were promising.

The vaccine, called a DNA vaccine, uses genes from the virus to create an immune response. It was first given to volunteers last August as concern spread over a cluster of Zika cases in Miami.

The new phase of the vaccine tests began Wednesday at Baylor College of Medicine in Houston, one of 11 U.S. locations that will enroll up to 5,000 healthy adults, according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which developed the vaccine.

In a call with reporters on Friday, Fauci said initial results in 40 volunteers indicate that the vaccine produced an immune response against Zika and didn’t cause serious side effects.

Vaccine Push

  • Companies are developing novel DNA vaccines to protect against a range of infections and to treat cancer.

  • Astellas Pharma

    Cytomegalovirus

  • GeneOne Life Science

    Flu, hepatitis C

  • GeoVax Labs

    HIV

  • Ichor Medial Systems

    HIV, malaria, breast cancer, melanoma

  • Inovio Pharmaceuticals

    MERS, Ebola, Zika

  • Madison Vaccines

    Prostate cancer

  • Vical

    Herpes

The threat has waned since Zika spread across Latin America and reached the U.S. last summer, but Fauci cautioned that the virus could return. People who get the mosquito-borne virus generally have only mild symptoms, but infection during pregnancy has been linked to serious birth defects.

The vaccine being tested, as well as other DNA vaccines, contains genetic material from the virus which, once injected into muscle, trains the body to mount an immune response against the virus.

The appeal of DNA vaccines is that they can be designed quickly to counter emerging threats and are easier to manufacture than traditional vaccines. The NIH previously developed a DNA vaccine against West Nile virus, but it was never commercialized.

Companies developing DNA vaccines include Astella Pharma, Inovio Pharmaceuticals, and GeoVax, whose products aim to protect against malaria, peanut allergy, and some types of cancer. So far, however, no DNA vaccine has reached the market.

To prove that the Zika vaccine protects against infection, Fauci says, the trial will eventually be expanded to sites in Puerto Rico, Brazil, Peru, Costa Rica, Panama, and Mexico, where the virus is still being transmitted.

Keep Reading

Most Popular

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.